These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20127954)

  • 1. Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.
    Nilsson R; Mårtensson L; Eriksson SE; Sjögren HO; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1033-42. PubMed ID: 20127954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
    Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
    Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
    Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats.
    Mårtensson L; Nilsson R; Sjögren HO; Strand SE; Tennvall J
    Artif Organs; 2007 Apr; 31(4):312-6. PubMed ID: 17437500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
    Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
    J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Mar; 27(2):134-40. PubMed ID: 22229635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacologic basis for antibody-auristatin conjugate activity.
    Alley SC; Zhang X; Okeley NM; Anderson M; Law CL; Senter PD; Benjamin DR
    J Pharmacol Exp Ther; 2009 Sep; 330(3):932-8. PubMed ID: 19498104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
    Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
    Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
    McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
    Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    J Nucl Med; 2007 Feb; 48(2):269-76. PubMed ID: 17268025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
    Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
    Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
    Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.